
Season 1 · Episode 49
HITshow Daily: October 2, 2025 (Thursday)
October 3, 20259m 11s
Audio is streamed directly from the publisher (media.blubrry.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Today on HITshow:
Today’s top story: the federal shutdown is more than politics — Teresa Vaughn walks providers through a detailed checklist on compliance, telehealth, hospital-at-home, finance, and research. Also: UnitedHealth hires Duke’s AI leader as Chief Scientist, Hackensack pairs dogs with AI for cancer detection, Omada launches a nutrition AI for chronic care, and the federal government calls on Eli Lilly and Pfizer to boost production of key drugs.
HOST: Steve Daily
📍 Providers / Government — Teresa VaughnThe shutdown fallout is hitting operations: CMS survey triage, telehealth flex expirations, Hospital-at-Home pause, and looming safety-net cuts. Vaughn shares the following checklist for health system leaders:
Quality & Compliance: Focus on IJ, EMTALA, dialysis.
Access & Scheduling: Update telehealth workflows for therapy and mental health.
Capacity: Reallocate staff and beds with Hospital-at-Home paused.
Finance: Model DSH and rural add-on reductions through Q4.
Community: Coordinate with FQHCs to smooth referrals.
Innovation & Research: Expect device and grant delays; adjust timelines.
📍 AI & Payers — Jade RomeroUnitedHealth names Duke’s Michael Pencina as Chief AI Scientist, signaling a credibility-first push to scale responsible AI.
📍 Providers / Research — Logan StokesHackensack Meridian partners with Israel-based startup SpotitEarly to validate canine scent + AI for early cancer detection — a message to providers that bold research can be a differentiator.
📍 Digital Health — Nate CollierOmada Health debuts “Meal Map,” an AI nutrition tool for cardiometabolic patients — early pilots show engagement gains.
📍 Pharma & Policy — Peter BetterworthThe administration asks Eli Lilly to ramp production of insulin, and Pfizer to increase productoin of Ibrance, and Lipitor — raising supply and formulary planning questions for hospitals.
🎧 Subscribe here or wherever you listen to podcasts, and if you like our show, please follow us on LinkedIn at https://www.linkedin.com/company/hit.show.
HITshow is made possible by HLTH 2025.